Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Galli

Showing results (131-140 of 179) with videos related to

Pageof 18
Sort By:
Journal of Global Antimicrobial Resistance|November 19, 2022
Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failuresRoberta Gagliardini, Patrizia Lorenzini, Alessandro Cozzi-Lepri, et al.
Plos One|November 1, 2017
Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected malesCristina Rovelli, Andrea Poli, Laura Galli, et al.
HIV Medicine|December 1, 2022
Subclinical atherosclerosis as detected by carotid ultrasound and associations with cardiac and HIV-specific risk factors; the Archi-Prevaleat projectPaolo Maggi, Elena Delfina Ricci, Camilla Muccini, et al.
BMC Infectious Diseases|January 13, 2017
A pilot study of brisk walking in sedentary combination antiretroviral treatement (cART)- treated patients: benefit on soluble and cell inflammatory markersMatteo Bonato, Laura Galli, Laura Passeri, et al.
International Journal of Antimicrobial Agents|March 4, 2023
Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimenRossana Scutari, Laura Galli, Claudia Alteri, et al.
Journal of Medical Virology|December 1, 2023
Mpox DNA clearance in semen over 6-month follow-upCaterina Candela, Laura Galli, Alberto Rizzo, et al.
Journal of the International AIDS Society|November 15, 2014
Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT studyVincenzo Spagnuolo, Laura Galli, Alba Bigoloni, et al.
Antiviral Therapy|April 14, 2010
Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapyAntonella Castagna, Laura Galli, Carlo Torti, et al.
The Journal of Antimicrobial Chemotherapy|February 3, 2012
Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 countsSilvia Nozza, Filippo Canducci, Laura Galli, et al.
Plos One|August 2, 2017
Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patientsNicola Gianotti, Andrea Poli, Laura Galli, et al.
Pageof 18

Showing results (131-140 of 179) with videos related to

Sort By:
Pageof 18
Journal of Global Antimicrobial Resistance|November 19, 2022
Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failuresRoberta Gagliardini, Patrizia Lorenzini, Alessandro Cozzi-Lepri, et al.
Plos One|November 1, 2017
Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected malesCristina Rovelli, Andrea Poli, Laura Galli, et al.
HIV Medicine|December 1, 2022
Subclinical atherosclerosis as detected by carotid ultrasound and associations with cardiac and HIV-specific risk factors; the Archi-Prevaleat projectPaolo Maggi, Elena Delfina Ricci, Camilla Muccini, et al.
BMC Infectious Diseases|January 13, 2017
A pilot study of brisk walking in sedentary combination antiretroviral treatement (cART)- treated patients: benefit on soluble and cell inflammatory markersMatteo Bonato, Laura Galli, Laura Passeri, et al.
International Journal of Antimicrobial Agents|March 4, 2023
Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimenRossana Scutari, Laura Galli, Claudia Alteri, et al.
Journal of Medical Virology|December 1, 2023
Mpox DNA clearance in semen over 6-month follow-upCaterina Candela, Laura Galli, Alberto Rizzo, et al.
Journal of the International AIDS Society|November 15, 2014
Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT studyVincenzo Spagnuolo, Laura Galli, Alba Bigoloni, et al.
Antiviral Therapy|April 14, 2010
Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapyAntonella Castagna, Laura Galli, Carlo Torti, et al.
The Journal of Antimicrobial Chemotherapy|February 3, 2012
Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 countsSilvia Nozza, Filippo Canducci, Laura Galli, et al.
Plos One|August 2, 2017
Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patientsNicola Gianotti, Andrea Poli, Laura Galli, et al.
Pageof 18